Overview

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
Phase:
Phase 4
Details
Lead Sponsor:
West Penn Allegheny Health System
Treatments:
Spironolactone